MDR Article 52(8): Custom-Made Devices Skip CE Marking — Not Always Scrutiny

Article 52(8) of the EU MDR does something most summaries flatten into one sentence: it exempts custom-made devices from the standard conformity assessment procedures — no CE mark, no Declaration of Conformity. What gets dropped in the summary is the second subparagraph, sitting in the same clause, that puts a Notified Body back into the picture for one category: Class III custom-made implantable devices. Teams that read the first half of Article 52(8) and stop there build a compliance program with a gap exactly where the regulation put a requirement.

What the Article 52(8) exemption actually covers

A custom-made device, under the MDR's definition, is made to an individual written prescription from someone with the relevant professional qualifications, carries design characteristics specific to that prescription, and is intended for the sole use of a particular patient. Devices that meet that test skip the conformity assessment procedures set out elsewhere in Article 52 and do not carry the CE mark. In their place, the manufacturer follows the EU MDR & IVDR procedure in Annex XIII and draws up the statement described in its Section 1 before the device reaches the patient. That statement is a different legal instrument from a Declaration of Conformity — it identifies the manufacturer and every manufacturing site, the device, the named patient, and the prescriber, rather than certifying conformity against the general safety and performance requirements the way a standard device's documentation does.

The carve-back: Class III custom-made implantables

Article 52(8)'s second subparagraph does not leave Class III custom-made implantable devices — a category that includes much of the custom orthopedic, dental, and cranial implant work driving demand for implantable device programs — inside the general exemption. These devices are instead subject to the conformity assessment procedure in Annex IX Chapter I, which audits the manufacturer's quality management system rather than reviewing each device individually. The regulation gives manufacturers an alternative: the Annex XI Part A production quality assurance route in place of the Annex IX Chapter I assessment. Either way, a Notified Body enters the picture before the device is placed on the market — the one point at which "custom-made" and "no Notified Body involvement" stop being the same statement.

• Annex IX Chapter I. A quality-management-system assessment of the manufacturer, parallel in structure to the standard conformity assessment routes most manufacturers already recognize — applied here to a population many assume is exempt from Notified Body review altogether.
• Annex XI Part A. The production quality assurance alternative Article 52(8) names explicitly — a real choice, not a fallback, and one some manufacturers do not realize they have.
• Annex XIII still applies. The Section 1 statement is required regardless of which assessment route the Class III implantable manufacturer takes; the Notified Body assessment is additive, not a replacement for it.
• No CE mark, even then. Passing the Annex IX or Annex XI assessment does not convert the device into a CE-marked product — the Article 52(8) exemption from CE marking holds for the device itself.

Custom-made does not mean unreviewed. It means a different reviewer, for most of the category, and the same reviewer plus a quality-system audit for Class III implantables. Reading Article 52(8) past the first subparagraph

Custom-made, patient-matched, or adaptable — MDCG 2021-3's dividing line

The category manufacturers most often misclassify is not a Class III implantable at all — it is the growing population of 3D-printed, patient-specific devices that resemble custom-made devices without legally being one. MDCG 2021-3 draws the line manufacturers need: a custom-made device requires an individual written prescription and is not mass-produced. A patient-matched device — produced from a scan and fitted to anatomy, but within a predefined design envelope and without an individual prescription — is treated as a standard device, requiring full CE marking and Notified Body involvement where its classification calls for one. An adaptable device, mass-produced and adjusted at the point of care, follows the same standard path. 3D printing and patient-specific geometry do not, by themselves, qualify a device as custom-made; the guidance is not a binding Commission document, but it is the operative interpretive reference manufacturers and Notified Bodies are working from, and the distinction has real conformity-assessment consequences on either side of it.

None of this is a large program. It is a classification test applied honestly, a statement built to the Annex XIII content requirements, and — for the Class III implantable subset — a Notified Body relationship most custom-device manufacturers did not expect to need. The manufacturers who get surprised are the ones who read "custom-made devices are exempt from conformity assessment" as the whole rule instead of the first half of it. If you have not tested your device population against MDCG 2021-3 directly, or confirmed where your Class III implantable certificates stand after the Article 120(3f) window closed, that is the place to start; our EU MDR & IVDR work exists for exactly this kind of classification gap.